The combination of curcumin with tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), a potent anti-cancer and inducer of apoptosis, have become an adjuvant therapy to improve the management of PCa disease, specifically AIPC. Here, TNFSF10 is linked to posterior cortical atrophy.